Usefulness and robustness of Immunoscore for personalized management of cancer patients

Florence Marliot; Franck Pagès; Jérôme Galon

doi:10.1080/2162402X.2020.1832324

Usefulness and robustness of Immunoscore for personalized management of cancer patients

Oncoimmunology. 2020 Oct 13;9(1):1832324. doi: 10.1080/2162402X.2020.1832324.

Authors

Florence Marliot^{1

2

3

4}, Franck Pagès^{1

2

3

4}, Jérôme Galon^{1

2

3}

Affiliations

¹ INSERM, Laboratory of Integrative Cancer Immunology, Paris, France.
² Equipe Labellisée Ligue Contre le Cancer, Paris, France.
³ Centre de Recherche DES Cordeliers, Sorbonne Université, Université de Paris, Paris, France.
⁴ Immunomonitoring Platform, Laboratory of Immunology, AP-HP, Assistance Publique-Hopitaux de Paris, Georges Pompidou European Hospital, Paris, France.

Abstract

This review details the analytical performance characteristics of the consensus Immunoscore, measuring the immune response to cancer, improving the estimation of risk of recurrence, and predicting response to treatment for patients with colon cancer. The analytical validation of Immunoscore has been documented. Immunoscore is a robust, reproducible, quantitative, and standardized immune assay, with a high prognostic performance, independent of all of the prognostic markers currently used in clinical practice. Immunoscore evaluation within the tumor microenvironment is clinically relevant, and Immunoscore was recently introduced into ESMO Clinical Practice Guidelines for colon cancer and into the WHO classification of the Digestive System Tumors. This paves the way for the use of Immunoscore in clinical practice in colorectal tumors and likely soon in many other solid tumors.

Keywords: Immunoscore; cancer classification; chemotherapy; immunity; phase 3 trial; predictive; prognosis; tumor microenvironment.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Colonic Neoplasms* / diagnosis
Colorectal Neoplasms*
Humans
Neoplasm Recurrence, Local
Prognosis
Tumor Microenvironment